Teva Pharmaceutical Raises Full-Year Outlook Following Strong Q3 Performance
Teva Pharmaceutical (TEVA) shares rose in premarket trading after the company reported third-quarter financial results that exceeded market expectations. The generic and innovative drugmaker attributed its strong performance to robust sales from its leading innovative brands. In addition to the quarterly beat, Teva raised its full-year financial outlook for 2026. This guidance adjustment reflects increased confidence in the company's revenue trajectory driven by its core product portfolio.
Tickers: $TEVA